GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Abiraterone is under clinical development by Austhera BioSciences and currently in Phase II for Hormone-Sensitive Prostate Cancer.

NKX-019 is under clinical development by Nkarta and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate (PTSR ...

SBP-101 is under clinical development by Spark Biopharma and currently in Phase I for Glioblastoma Multiforme (GBM).

CSL -889 is under development for the treatment of acute vascular occlusive crisis (VOC) in sickle cell disease. The drug candidate consists of plasma-derived hemopexin. It is administered through ...

NUC-7738 is under clinical development by NuCana and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...

ENA-001 is under clinical development by Enalare Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Long-Acting Injectable Program is under clinical development by Intra-Cellular Therapies and currently in Phase I for Schizoaffective Disorder.

CY-101 is under clinical development by Cytovation and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...

Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Myelodysplastic Syndrome.

AMT-162 is under development for the treatment of amyotrophic lateral sclerosis. It comprises of Adeno-associated virus rh 10 (AAVrh10) encoding an artificial microRNA (miRNA) that targets SOD1 and ...

HPV-16 E7 is under clinical development by Gilead Sciences and currently in Phase II for Oropharyngeal Cancer.